30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Mark Foley

Track

Insider profile

Currently holds positions in Revance Therapeutics Inc, SI-BONE Inc, ZELTIQ Aesthetics Inc and Revance Therapeutics Inc

Performance

Overall performance
3.5
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 11% 8.2% 15.1%
Success rate 97% 68% 82%
Transactions
6 33% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 145%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Revance Therapeutics Inc Sept. 5, 2017 -
Independent Director SI-BONE Inc June 17, 2019 -
President, Chief Executive Officer ZELTIQ Aesthetics Inc April 28, 2017 -
President, Chief Executive Officer, Director Revance Therapeutics Inc Oct. 13, 2019 -
Independent Director Revance Therapeutics Inc Sept. 5, 2017 - Oct. 13, 2019
Chairman of the Board, President, Chief Executive Officer ZELTIQ Aesthetics Inc Jan. 1, 2015 - April 28, 2017
President, Chief Executive Officer, Director ZELTIQ Aesthetics Inc Nov. 19, 2012 - Jan. 1, 2015
President, Chief Executive Officer, Interim Chief Financial Officer, Director ZELTIQ Aesthetics Inc Aug. 23, 2012 - Nov. 19, 2012
Interim President, Chief Executive Officer, Interim Chief Financial Officer, Director ZELTIQ Aesthetics Inc Aug. 9, 2012 - Aug. 23, 2012
Interim President and Chief Executive Officer, Director ZELTIQ Aesthetics Inc April 19, 2012 - Aug. 9, 2012
Director ZELTIQ Aesthetics Inc May 1, 2010 - April 19, 2012
Mark Foley's trades of Glaukos Corp's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-28 2025-02-26
US Glaukos Corp (GKOS)
S Sale
83,107 +32.6%
268.41
US$2,585,649 		83,107 +32.6% 268.41 US$2,585,649
2025-02-26 2025-02-26
US Glaukos Corp (GKOS)
PrS Proposed sale
90,381
60.62
US$3,174,598 		90,381 60.62 US$3,174,598
2024-03-08 2024-03-06
B Purchase
7,189 +2.4%
329.60
US$2,766,076 		7,189 +2.4% 329.60 US$2,766,076
2024-02-26 2024-02-23
US Glaukos Corp (GKOS)
S Sale
4,560 -12.1%
92.87
US$423,487 		4,560 -12.1% 92.87 US$423,487
2024-02-23 2024-02-23
US Glaukos Corp (GKOS)
PrS Proposed sale
4,560
92.87
US$423,482 		4,560 92.87 US$423,482
2023-08-04 2023-08-03
PlS Planned sale
26,279 -3.0%
22.57
US$593,151 		26,279 -3.0% 22.57 US$593,151
2023-08-03 2023-08-03
PrS Proposed sale
26,279
22.49
US$591,115 		26,279 22.49 US$591,115
2023-07-05 2023-07-03
PlS Planned sale
26,279 -2.9%
24.94
US$655,333 		26,279 -2.9% 24.94 US$655,333
2023-07-03 2023-07-03
PrS Proposed sale
26,279
24.94
US$655,398 		26,279 24.94 US$655,398
2023-06-13 2023-06-09
PlS Planned sale
31,279 -3.4%
30.72
US$960,928 		31,279 -3.4% 30.72 US$960,928
2023-06-09 2023-06-09
PrS Proposed sale
31,279
30.72
US$960,901 		31,279 30.72 US$960,901
2023-05-16 2023-05-15
S Sale
70,447 -7.1%
34.55
US$2,433,725 		70,447 -7.1% 34.55 US$2,433,725
2023-05-15 2023-05-15
PrS Proposed sale
447
34.56
US$15,450 		447 34.56 US$15,450
2023-05-12 2023-05-12
PrS Proposed sale
70,000
33.40
US$2,338,000 		70,000 33.40 US$2,338,000
2023-03-09 2023-03-09
S Sale
70,390 -7.9%
31.59
US$2,223,360 		70,390 -7.9% 31.59 US$2,223,360
2023-03-09 2023-03-08
PrS Proposed sale
75,000
33.00
US$2,475,000 		75,000 33.00 US$2,475,000
2021-11-29 2021-11-29
B Purchase
40,000 +56.4%
12.90
US$515,924 		40,000 +56.4% 12.90 US$515,924
2016-03-23 2016-03-22
PlS Planned sale
9,698 -2.6%
25.01
US$242,568 		9,698 -2.6% 25.01 US$242,568
2016-03-22 2016-03-18
PlS Planned sale
1,272 -0.3%
25.01
US$31,816 		1,272 -0.3% 25.01 US$31,816